|
ASTX727 Clinical Trials
9 actively recruiting trials across 4 locations
Also known as: C-DEC, INQOVI, Inqovi, Oral decitabine and cedazuridine
Pipeline
Phase 1: 7Phase 2: 1Phase 1/2: 1
Top Sponsors
- Taiho Oncology, Inc.2
- M.D. Anderson Cancer Center2
- Royal Marsden NHS Foundation Trust1
- Pamela Munster1
- Memorial Sloan Kettering Cancer Center1
Indications
- Cancer9
- Acute Myeloid Leukemia4
- Myelodysplastic Syndromes2
- Neurological Cancer1
- Malignant Peripheral Nerve Sheath Tumors (MPNST)1
Houston, Texas4 trials
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
M D Anderson Cancer Center
Phase 1/2
Phase 1
Phase 1
Other2 trials
San Francisco, California1 trial
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
University of California, San Francisco
Phase 1
Boston, Massachusetts1 trial
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Massachusetts General Hospital Cancer Center
Phase 1
Basking Ridge, New Jersey1 trial
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.